The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Europe idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 8.00% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Idiopathic pulmonary fibrosis (IPF) is a persistent lung infection that causes scarring of the lungs. This hampers the oxygen-carrying functionality of the organ, thereby resulting in breathing difficulties. Some of the common symptoms include a persistent dry cough, fatigue, loss of appetite, and swollen limbs. IPF is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. It can be treated by prescribing anti-fibrotic drugs and supportive treatment options, such as oxygen therapy and palliative care.
The Europe IPF treatment market is primarily being driven by the increasing prevalence of chronic lung and fibrotic diseases, especially in the geriatric population. This can be attributed to changing living standards, high smoking rates, and increasing environment pollutants. Other than this, increasing health consciousness amongst consumers and rising awareness regarding the presence of effective IPF preventive and management strategies are catalyzing the market growth. In line with this, increasing government expenditures for the development of existing healthcare systems and rapid advancements in diagnostic techniques are acting as another growth-inducing factor. The implementation of favorable regulatory policies and continuous investments in research and development (R&D) activities for introducing novel medicines are further creating a positive outlook for the market in the region.
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe idiopathic pulmonary fibrosis treatment market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Drug Class, End User, Country|
|Region Covered||Germany, France, United Kingdom, Italy, Spain|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at